Development and Implementation of a Risk Assessment Tool for Chemotherapy-Induced Neutropenia
Purpose/Objectives: To evaluate a tool developed and implemented to help practitioners assess the risk of chemotherapy-induced neutropenia (CIN) and its complications in patients with nonleukemia cancer types.
Design: Retrospective survey of chart records.
Setting: Community-based oncology practice.
Sample: The medical records of 85 adult patients treated with new courses of chemotherapy, regardless of the cancer type or stage; 50 charts belonged to patients treated before the implementation of the tool and 35 to patients evaluated with the tool.
Methods: A risk assessment tool for CIN that was developed using risk factors from published studies and national guidelines was implemented. Patients who were found to be at increased risk for CIN were given colony-stimulating factor (CSF) support starting with the first chemotherapy cycle. The effectiveness of the tool was evaluated by comparing clinical outcomes before and after the implementation of the risk assessment tool.
Main Research Variables: Febrile neutropenia, IV antibiotic use, hospitalization for neutropenia, and chemotherapy dose reductions and delays.
Findings: Chemotherapy dose delays, febrile neutropenia, treatment with IV antibiotics, and hospitalization for neutropenia occurred less frequently in patients assessed with the tool and managed with the algorithm for CSF use than in those who were not assessed.
Conclusions: The Risk Assessment for Neutropenic Complications Tool is effective in helping practitioners determine which patients are at high risk for CIN and its complications.
Implications for Nursing: By using the tool to identify patients treated with chemotherapy who need growth factor support, nurses can help to reduce the incidence of neutropenia and its complications.
Jump to a section
References
Beveridge, R., Del Prete, S., Fausel, C., Leather, H., McFarland, H., & Valley, A. (Eds.). (2001). Guide to the management of selected adverse events associated with cancer chemotherapy. Thousand Oaks, CA: Amgen.
Beveridge, R.A., Reitan, J.F., Fausel, C., Leather, H., McFarland, H., Rifkin, R.M., et al. (Ed.). (2004). Guide to selected cancer chemotherapy regimens and associated adverse events (5th ed.). Thousand Oaks, CA: Amgen.
Bodey, G.P., Buckley, M., Sathe, Y.S., & Freireich, E.J. (1966). Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328-340.
Bonadonna, G., & Valagussa, P. (1981). Dose-response effect of adjuvant chemotherapy in breast cancer. New England Journal of Medicine, 304, 10-15.
Budman, D.R., Berry, D.A., Cirrincione, C.T., Henderson, I.C., Wood, W.C., Weiss, R.B., et al. (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute, 90, 1205-1211.
Caggiano, V., Stolshek, B., Delgado, D., & Carter, B. (2001). First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkin's lymphoma (IGL) patients on standard-dose CHOP therapy [Abstract 1810]. Blood, 11, 431a.
Crawford, J., Dale, D.C., & Lyman, G.H. (2004). Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer, 100, 228-237.
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine, 325, 164-170.
Epelbaum, R., Faraggi, D., Ben-Arie, Y., Ben-Shahar, M., Haim, N., Ron, Y., et al. (1990). Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer, 66, 1124-1129.
Fortner, B.V., Stolshek, B., Tauer, K.W., Okon, T.H., Durrence, H., White, H., et al. (2002). Final analysis: Chemotherapy induced neutropenia (CIN) is associated with lower quality of life (QoL) in patients (pts) with cancer [Abstract 640P]. Annals of Oncology, 13(5, Suppl.), 174.
Fortner, B.V., Tauer, K., Zhu, L., Okon, T.A., Moore, K., Templeton, D., et al. (2004). Medical visits for chemotherapy and chemotherapy-induced neutropenia: A survey of the impact on patient time and activities. BMC Cancer, 4, 22.
Glynn-Tucker, E. (2002, April). A multidisciplinary performance improvement project for management of febrile neutropenia. Presentation at the ONS 27th Annual Congress, Washington, DC.
Green, M.D., Koelbl, H., Baselga, J., Galid, A., Guillem, V., Gascon, P., et al. (2003). A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology, 14, 29-35.
Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S., Jones, S.E., Shogan, J., Savin, M., et al. (2002). Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Journal of Clinical Oncology, 20, 727-731.
Houston, D. (1997). Supportive therapies for cancer chemotherapy patients and the role of the oncology nurse. Cancer Nursing, 20, 409-413.
Kuderer, N., Cosler, L.E., Crawford, J., Dale, D.C., & Lyman, G.H. (2002). Cost and mortality associated with febrile neutropenia in adult cancer patients [Abstract 998]. Proceedings of the American Society of Clinical Oncology, 21, 250a.
Kwak, L.W., Halpern, J., Olshen, R.A., & Horning, S.J. (1990). Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology, 8, 963-977.
Lepage, E., Gisselbrecht, C., Haioun, C., Sebban, C., Tilly, H., Bosly, A., et al. (1993). Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Annals of Oncology, 4, 651-656.
Lyman, G.H., Dale, D.C., & Crawford, J. (2003). Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. Journal of Clinical Oncology, 21, 4524-4531.
Lyman, G.H., Dale, D.C., Friedberg, J., Crawford, J., & Fisher, R.I. (2004). Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. Journal of Clinical Oncology, 22, 4302-4311.
Lyman, G.H., Kuderer, N.M., Crawford, J., & Dale, D. (2003). Economic impact of pegfilgrastim use based on the risk of febrile neutropenia (febrile neutropenia) in NHL patients treated with CHOP [Abstract 2384]. Proceedings of the American Society of Clinical Oncology, 22, 593.
Maxwell, C., & Winkler, J. (2002, April). Nurse driven neutropenia management guidelines: Improving patient outcomes through evidence-based practice. Presentation at the ONS 27th Annual Congress, Washington, DC.
National Comprehensive Cancer Network. (2004). NCCN clinical practice guidelines in oncology: Fever and neutropenia. Retrieved July 12, 2005, from http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf
National Comprehensive Cancer Network. (2005). NCCN clinical practice guidelines in oncology: Myeloid growth factors in cancer treatment. Retrieved June 30, 2005, from http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf
Okon, T.A., Fortner, B.V., Schwartzberg, L., Tauer, K.T., Durrence, H., Kovacs, A., et al. (2002). Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [Abstract 2920]. Proceedings of the American Society of Clinical Oncology, 21, 275b.
Ozer, H., Armitage, J.O., Bennett, C.L., Crawford, J., Demetri, G.D., Pizzo, P.A., et al. (2000). 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Journal of Clinical Oncology, 18, 3558-3585.
Ropka, M.E., Padilla, G., & Gillespie, T.W. (2005). Risk modeling: Applying evidence-based risk assessment in cancer nursing practice. Oncology Nursing Forum, 32, 49-56.
Stricker, C.T., & Sullivan, J. (2003). Evidence-based oncology oral care clinical practice guidelines: Development, implementation, and evaluation. Clinical Journal of Oncology Nursing, 7, 222-227.
Timmer-Bonte, J., Biesma, B., Smit, J., Wilschut, F., Akkermans, J., De Boo, G., et al. (2004). Prevention of chemotherapy-induced febrile neutropenia (febrile neutropenia) by antibiotics (AB) versus antibiotics plus granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC): A randomized phase III study [Abstract 8002]. Proceedings of the American Society of Clinical Oncology, 23, 726.
Trillet-Lenoir, V., Green, J., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer, 29A, 319-324.
Vogel, C.L., Wojtukiewicz, M.Z., Carroll, R.R., Tjulandin, S.A., Barajas-Figuroa, L.J., Wiens, B.L., et al. (2005). First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo controlled phase III study. Journal of Clinical Oncology, 23, 1178-1184.
White, N., Maxwell, N., Michelson, J., & Bedell, C. (2005). Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nursing, 28, 62-69.